


Highlights of This Issue 2823

REVIEW

- 2825** Mechanisms of Resistance to Antibody–Drug Conjugates
Frank Loganzo, Matthew Sung, and Hans-Peter Gerber

SMALL MOLECULE THERAPEUTICS

- 2835** Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
 Jun Chen, Taisei Kinoshita, Juthamas Sukbuntherng, Betty Y. Chang, and Laurence Elias
- 2845** Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different *KIT* Mutations
Yemarshet K. Gebreyohannes, Patrick Schöffski, Thomas Van Looy, Jasmien Wellens, Lise Vreys, Jasmien Cornillie, Ulla Vanleeuw, Dana T. Aftab, Maria Debiec-Rychter, Raf Sciot, and Agnieszka Wozniak
- 2853** Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts
Jerec W. Ricci, Debbie M. Lovato, Virginia Severns, Larry A. Sklar, and Richard S. Larson
- 2863** Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells
Eiman Mukhtar, Vaqar Mustafa Adhami, Imtiaz Ahmad Siddiqui, Ajit Kumar Verma, and Hasan Mukhtar
- 2875** Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Stepana Boukalova, Jan Stursa, Lukas Werner, Zuzana Ezrova, Jiri Cerny, Ayenachew Bezawork-Geleta, Alena Pecinova, Lanfeng Dong, Zdenek Drahota, and Jiri Neuzil
- 2887** Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer
Jianfeng Lu, Donna McEachern, Shunqiang Li, Matthew J. Ellis, and Shaomeng Wang

- 2894** Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer
Yan Huang, Lenard M. Lichtenberger, Morgan Taylor, Justin N. Bottsford-Miller, Monika Haemmerle, Michael J. Wagner, Yasmin Lyons, Sunila Pradeep, Wei Hu, Rebecca A. Previs, Jean M. Hansen, Dexing Fang, Piotr L. Dorniak, Justyna Filant, Elizabeth J. Dial, Fangrong Shen, Hiroto Hatakeyama, and Anil K. Sood
- 2905** Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells
Sagar Uttarkar, Therese Piontek, Sandeep Dukare, Caroline Schomburg, Peter Schlenke, Wolfgang E. Berdel, Carsten Müller-Tidow, Thomas J. Schmidt, and Karl-Heinz Klempnauer
- 2916** CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
Dan-Dan Wang, Ying Chen, Zi-Bo Chen, Fang-Jie Yan, Xiao-Yang Dai, Mei-Dan Ying, Ji Cao, Jian Ma, Pei-Hua Luo, Yong-Xin Han, Yong Peng, Ying-Hui Sun, Hui Zhang, Qiao-Jun He, Bo Yang, and Hong Zhu
- 2926** Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma
Samuele Cazzamalli, Alberto Dal Corso, and Dario Neri
- 2936** Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation
Nada Lalous, Eric Leblanc, Ravi S.N. Munuganti, Mohamed D.H. Hassona, Nader Al Nakouzi, Shannon Awrey, Helene Morin, Mani Roshan-Moniri, Kriti Singh, Sam Lawn, Takeshi Yamazaki, Hans H. Adomat, Christophe Andre, Mads Daugaard, Robert N. Young, Emma S. Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov
- LARGE MOLECULE THERAPEUTICS**
- 2946** Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
Lawrence J. Thomas, Laura Vitale, Thomas O'Neill, Ree Y. Dolnick, Paul K. Wallace, Hans Minderman, Lauren E. Gergel, Eric M. Forsberg, James M. Boyer, James R. Storey, Catherine D. Pilsmaker, Russell A. Hammond, Jenifer Widger, Karuna Sundarapandiyam, Andrea Crocker, Henry C. Marsh Jr, and Tibor Keler

Table of Contents

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2955** Knockdown of *Apolipoprotein E* Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na⁺/K⁺-ATPase Signalosome
Miao Liu, Li-Xing Feng, Peng Sun, Wang Liu, Tian Mi, Min Lei, Wanying Wu, Baohong Jiang, Min Yang, Lihong Hu, De-An Guo, and Xuan Liu
- 2966** Ascoclhorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Xiaoyun Dai, Kwang Seok Ahn, Ling Zhi Wang, Chulwon Kim, Amudha Deivasigamni, Frank Arfuso, Jae-Young Um, Alan Prem Kumar, Young-Chae Chang, Dhiraj Kumar, Gopal C. Kundu, Junji Magae, Boon Cher Goh, Kam Man Hui, and Gautam Sethi
- 2977** The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development
Shuang Liu, Ramkrishna Mitra, Ming-Ming Zhao, Wenhong Fan, Christine M. Eischen, Feng Yin, and Zhongming Zhao
- 2987** The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells
Teresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, Harold G. Parkes, Richard Marais, Paul Workman, Martin O. Leach, and Mounia Belouèche-Babari
- 3000** Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Alfeu Zanotto-Filho, V. Pragathi Masamsetti, Eva Loranc, Sonal S. Tonapi, Aparna Gorthi, Xavier Bernard, Rosângela Mayer Gonçalves, José C.F. Moreira, Yidong Chen, and Alexander J.R. Bishop
- 3015** Mutant *BRAF* Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer
Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Shamit K. Dutta, Debabrata Mukhopadhyay, and Frank A. Sinicrope
- 3028** Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
Timothy A. Marlowe, Felicia L. Lenzo, Sheila A. Figel, Abigail T. Grapes, and William G. Cance

- 3040** Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba, Satoru Arata, Yasunari Kishino, Yasunori Murata, Sojiro Kusumoto, Hiroo Ishida, Takao Shirai, Takashi Hirose, Tsukasa Ohnishi, and Yasutsuna Sasaki
- 3055** STAT1 Promotes *KRAS* Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A
Shuo Wang, Cedric Darini, Laurent Désaubry, and Antonis E. Koromilas
- 3064** Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model
Gina Lee, Brenda Auffinger, Donna Guo, Tanwir Hasan, Marc Deheeger, Alex L. Tobias, Jeong Yeon Kim, Fatemeh Atashi, Lingjiao Zhang, Maciej S. Lesniak, C. David James, and Atique U. Ahmed

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 3077** Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Leon P. Pradel, Chia-Huey Ooi, Solange Romagnoli, Michael A. Cannarile, Hadassah Sade, Dominik Rüttinger, and Carola H. Ries
- 3087** ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis
Vinod Vijay Subhash, Shi Hui Tan, Mei Shi Yeo, Fui Leng Yan, Praveen C. Peethala, Natalia Liem, Vaidehi Krishnan, and Wei Peng Yong

MODELS AND TECHNOLOGIES

- 3097** Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Nicole Willemsen-Seegers, Judith R.F. de Vetter, Jelle Dylus, Antoon M. van Doornmalen, Jeffrey Kooijman, Masaaki Sawa, Suzanne J.C. van Gerwen, Jos de Man, Rogier C. Buijsman, and Guido J.R. Zaman



Table of Contents

3110 Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Miro J. Eigenmann, Nicolas Frances, Gerhard Hoffmann, Thierry Lavé, and Antje-Christine Walz

CORRECTION


3120 Correction: Antagonists of IGF: Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions

3121 Acknowledgment to Reviewers

 **AC icon indicates Author Choice**
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover image shows a Pearson correlation matrix of 51 anti-cancer agents analyzed in the Oncolines and NCI-60 cancer cell line panels (blue: high correlation, orange: negative correlation). The left triangle shows clusters and correlations using data from the Oncolines panel. The right triangle is identical to the left one, only based on NCI-60 data. Both data sets reveal similar clusters (some classes are indicated). Read more on the Oncolines™ cancer cell line profiling study in the article by Uitdehaag and colleagues from page 3097 of this issue.



Molecular Cancer Therapeutics

15 (12)

Mol Cancer Ther 2016;15:2823-3124.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/15/12>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.